Drug intelligence / Profile preview

Yiyang Pill

Development stage: Preclinical
Administration: Oral

Overview

Yiyang Pill is an oral intervention currently undergoing a randomized controlled double-blind clinical study. It is being investigated for its potential to address cardiovascular adverse reactions that occur following TSH inhibition treatment after thyroid cancer operation. Given the context of the clinical trial being run by Chinese institutions and the name format, it is likely a Traditional Chinese Medicine (TCM) formulation.

Other names: Yiyang益养丸

Targets

NOS3 (eNOS)PDE5 (Phosphodiesterase 5A)ESR1 (ERα)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Yiyang Pill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiyang Pill.

Explore the full profile